A Study Of GLP-1–Based Therapies On Sexual Health In Postmenopausal Women

Overview

About this study

The purpose of this study is to characterize changes in sexual function, as measured by the Female Sexual Function Index (FSFI) and the Revised Female Sexual Function Index (FSFI-R), in postmenopausal women receiving GLP-1–based therapies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Sexually active postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorectomy).

  • Age 46-60 years old.

  • BMI ≥ 30 kg/m², or ≥ 27 kg/m² in the presence of adiposity-related comorbidities (e.g., hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea).

  • Active weight loss interventions with FDA-approved obesity medications or bariatric surgery.

Exclusion Criteria:

  • Non Postmenopausal women

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/18/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Maria Hurtado Andrade

Contact us for the latest status

Contact information:

Maria Hurtado Andrade

(904) 953-2327

hurtado.mariadaniela@mayo.edu

More information

Publications

Publications are currently not available